A discussion between Dr. Daniel Pollyea and Dr. Andre Schuh (Fall 2021)

In this episode, Dr. Daniel Pollyea and Dr. Andre Schuh share their experience with using novel therapies in managing AML patients ineligible for intensive chemotherapy. They provide their take on frailty in the context of recent additions to the AML treatment armamentarium and further discuss factors that impact therapeutic decision-making, from patient and disease characteristics to the access and reimbursement landscape.

Daniel A. Pollyea, MD, MS Associate Professor of Medicine Clinical Director of Leukemia Services Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine

Andre Schuh,BSc, MD, FRCPC Staff Physician, University Health Network/Princess Margaret Cancer Centre Toronto, ON

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.